Aerie Pharmaceuticals Inc (NASDAQ:AERI) Could Improve Your Long Portfolio After Less Shorts Reported

March 17, 2018 - By Marguerite Chambers

 Aerie Pharmaceuticals Inc (NASDAQ:AERI) Could Improve Your Long Portfolio After Less Shorts Reported

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It increased, as 14 investors sold Aerie Pharmaceuticals, Inc. shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported.
Phoenix Invest Adviser reported 300 shares. Nationwide Fund Advsrs owns 71,609 shares. State Board Of Administration Of Florida Retirement Systems has invested 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Baker Bros Advsr Lp owns 299,356 shares for 0.12% of their portfolio. Highland L P invested in 35,000 shares. Laurion Mgmt L P accumulated 0% or 4,800 shares. Columbus Circle Invsts accumulated 519,806 shares or 0.43% of the stock. Colony Grp Ltd Co accumulated 5,370 shares. Fmr Ltd Limited Liability Company reported 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Neuberger Berman Gru Limited Liability Corporation holds 0% or 25,000 shares in its portfolio. Aqr Capital Mgmt Limited Co accumulated 0% or 35,078 shares. Federated Investors Pa holds 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 5,678 shares. Partner Fund Mngmt L P accumulated 2.41 million shares. Prudential accumulated 56,520 shares or 0% of the stock. Millennium Lc reported 0.02% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) registered a decrease of 0.35% in short interest. AERI’s total short interest was 3.94M shares in March as published by FINRA. Its down 0.35% from 3.95 million shares, reported previously. With 488,600 shares average volume, it will take short sellers 8 days to cover their AERI’s short positions. The short interest to Aerie Pharmaceuticals Inc’s float is 14.68%.

The stock increased 0.87% or $0.5 during the last trading session, reaching $57.95. About 386,161 shares traded or 1.48% up from the average. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since March 17, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.29 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals has $10000 highest and $30 lowest target. $73.62’s average target is 27.04% above currents $57.95 stock price. Aerie Pharmaceuticals had 49 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Buy” on Thursday, October 5. The firm has “Buy” rating given on Wednesday, February 28 by Cantor Fitzgerald. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, October 11. The firm has “Buy” rating given on Tuesday, September 26 by Cowen & Co. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Thursday, September 17 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $65.0 target in Wednesday, August 16 report. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Tuesday, August 1 by Canaccord Genuity. The rating was reinitiated by H.C. Wainwright with “Buy” on Friday, February 16. Needham maintained the stock with “Buy” rating in Friday, September 15 report. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Mizuho on Wednesday, September 6.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.